Skip to main content
SpringerLink
Log in

Kardiometabolisches Risikomanagement

LDL: ein besonders Therapieziel bei Typ-2-Diabetes im Zeitalter der EBM?

  • Aktuell_Lipidsprechstunde
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004;53 Suppl 3:S39–47

    Article  CAS  PubMed  Google Scholar 

  2. ACCORD Study Group, Ginsberg HN, Elam MB et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362 (17):1563–74

    Google Scholar 

  3. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo- controlled trial. Lancet. 2004 Aug 21- 27;364(9435):685–96

    Article  CAS  PubMed  Google Scholar 

  4. Cannon CP et al. IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes. AHA 2014, Late Breaking Clinical Trials, LBCT.02: Anti-Lipid Therapy and Prevention of CAD, Montag, 17.11.2014. http://my.americanheart. org/idc/groups/ahamah-public/@ wcm/@sop/@scon/documents/downloadable/ ucm_469669.pdf

  5. Winkler K, Jacob S, Müller-Schewe T et al. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis. 2012 Jan;220(1):189–93

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brombeerweg 6, 78048, Villingen-Schwenningen, Deutschland

    Stephan Jacob (Praxis für Prävention und Therapie)

  2. Institut für Klinische Chemie und Laboratoriumsmedizin, Lipidambulanz, Universitätsklinikum Freiburg, Hugstetterstr. 55, 79106, Freiburg, Deutschland

    Karl Winkler

Authors
  1. Stephan Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Jacob.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jacob, S., Winkler, K. LDL: ein besonders Therapieziel bei Typ-2-Diabetes im Zeitalter der EBM?. CV 15, 25–28 (2015). https://doi.org/10.1007/s15027-015-0596-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-015-0596-x

Search

Navigation